AKT1 and glioblastoma: A multitude of signaling pathway cascades activated by EGFR are associated with GBM progression, e.g. activation of Cyclooxygenase-2 [10,11], K-RAS and AKT signaling [12], and mammalian target of rapamycin (mTOR) together with phosphatidyl-inositol-3-kinase (PI3K) pathways [13–16].